| Assessment Status | Rapid Review Complete |
| HTA ID | 22069 |
| Drug | Maribavir |
| Brand | Livtencity® |
| Indication | For the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant or solid organ transplant. |
| Assessment Process | |
| Rapid review commissioned | 11/11/2022 |
| Rapid review completed | 13/12/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of maribavir compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations March 2024.
